Venice Archer

6.1k citations
16 papers · 4.6k · 4 hit papers · h-index 9

Impact in

  • Oncology top 0.5%
    • Lung Cancer Research Studies
    • Colorectal Cancer Treatments and Studies
    • Cancer Immunotherapy and Biomarkers
    • HER2/EGFR in Cancer Research
    • Lung Cancer Treatments and Mutations
    • Lung Cancer Diagnosis and Treatment
    • Gastric Cancer Management and Outcomes

Papers in

    • Lung Cancer Treatments and Mutations 15
    • Lung Cancer Diagnosis and Treatment 3
    • Lung Cancer Research Studies 7
    • Colorectal Cancer Treatments and Studies 5
    • Cancer Immunotherapy and Biomarkers 3
    • Cancer Treatment and Pharmacology 1

Venice Archer

16 papers receiving 4.5k citations

Venice Archer's Hit Papers

Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial 2019 · 1.1k citations
1.1k0+7+14Years since publication50010001.5k

Peers

Venice Archer
Comparison fields: 5 of 96
  • Oncology 3.6k
  • Pulmonary and Respiratory Medicine 3.6k
  • Cancer Research 663
  • Hepatology 183
  • Molecular Biology 919
Replace Aleksandra Szczęsna with:
Aleksandra Szczęsna Poland
Davey B. Daniel United States
Bilal Piperdi United States
Mircea Dediu Romania
Jose R. Pereira Germany
Francesco Orlandi United States
Radj Gervais France
Tiziana Usari Italy
Maximiliano Van Kooten Argentina
Oleg Gladkov Russia
Venice Archer relative to Aleksandra Szczęsna Poland Aleksandra Szczęsna's profile →
Citations per field
00.5×
Aleksandra Szczęsna · 1×
Citations per year

Countries citing papers authored by Venice Archer

Since Specialization
Citations

This map shows the geographic impact of Venice Archer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Venice Archer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Venice Archer more than expected).

Fields of papers citing papers by Venice Archer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Venice Archer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Venice Archer. The network helps show where Venice Archer may publish in the future.

Co-authors

The 25 scholars most cited alongside Venice Archer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Venice Archer Line = papers co-authored together Venice Archer links everyone, so they are left out of the graph.

All Works

16 of 16 papers shown
#Work
1
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
Hit paper breakdown →
20051688
2
Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
Hit paper breakdown →
20091174
3
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
Hit paper breakdown →
20191137
4
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
Hit paper breakdown →
2010498
5 201846
6 201439
7 201619
8 201414
9 20219
10 20237
11 20225
12 20224
13 20203
14 20122
15 20192
16 20121

About Venice Archer

Venice Archer is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Hepatology and Surgery, having authored 16 papers that have together received 4.6k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (15 papers), Lung Cancer Research Studies (7 papers), Colorectal Cancer Treatments and Studies (5 papers), Cancer Genomics and Diagnostics (4 papers), Lung Cancer Diagnosis and Treatment (3 papers), Cancer Immunotherapy and Biomarkers (3 papers), Hepatocellular Carcinoma Treatment and Prognosis (2 papers) and Cancer Treatment and Pharmacology (1 paper). The work is most often cited by research in Oncology (3.6k citations), Pulmonary and Respiratory Medicine (3.6k citations), Cancer Research (663 citations), Hepatology (183 citations) and Molecular Biology (919 citations). Venice Archer has collaborated with scholars based in United Kingdom, Switzerland and Germany. Frequent co-authors include Joachim von Pawel, Martin Reck, Nick Thatcher, E.H. Tan, José Rodrigues Pereira, Kevin Carroll, Tudor–Eliade Ciuleanu, Sumitra Thongprasert, Kristine Pemberton and Purvish M. Parikh. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Journal of Thoracic Oncology, Lung Cancer and The Lancet Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact